When Myocardial Injury in Lupus Is Not Lupus: Probable Antimalarial‐Associated Cardiomyopathy Mimicking Lupus Myocarditis Authors: Diego Armando Pérez Covo, María Camila Bernal Beltrán, Diego Alejandro Ortega, Cristian Orlando Porras Bueno, Emilio José Juan Guardela, Carlos Hernán Calderón, Edward Andres Cáceres Méndez, Laura Valentina Omaña Álvarez, Alejandro Mariño Correa, Ángel Alberto García Peña Published: 2026 ABSTRACT ABSTRACTAntimalarial cardiotoxicity may mimic lupus myocarditis in systemic lupus erythematosus. We report a 53‐year‐old woman with chronic antimalarial exposure, myocardial injury, biventricular dysfunction, electrical abnormalities, low lupus activity, and no myocardial edema. Chloroquine withdrawal was followed by clinical improvement and left ventricular function recovery, supporting probable antimalarial‐associated cardiomyopathy. Introduction Cardiac involvement in systemic lupus erythematosus (SLE) is well recognized, and myocarditis is often suspected in patients presenting with chest pain, elevated cardiac biomarkers, new conduction abnormalities, arrhythmia, or ventricular dysfunction [1]. However, this clinical scenario represents a diagnostic challenge because inflammatory and non‐inflammatory etiologies may share overlapping clinical, electrocardiographic, and imaging features. Among these, chloroquine (CQ)‐ and hydroxychloroquine (HCQ)‐related cardiotoxicity remains an underrecognized but potentially modifiable cause of myocardial injury in patients with chronic antimalarial exposure [2]. Failure to consider this diagnosis may delay drug withdrawal and lead to progression toward heart failure (HF), clinically significant arrhythmias, device requirement, or death if exposure persists [3]. CQ/HCQ cardiotoxicity is uncommon but likely underdiagnosed. It has been associated with prolonged exposure, high cumulative doses, conduction abnormalities, ventricular hypertrophy, hypokinesia, and HF [4]. Mechanistically, CQ and HCQ act as lysosomotropic agents, increasing intralysosomal pH and impairing autophagic flux, which promotes acquired myocardial phospholipidosis. The resulting cytoplasmic vacuolization, myocyte hypertrophy, interstitial fibrosis, and conduction system involvement explain the broad spectrum of presentation, ranging from restrictive physiology and HF with preserved ejection fraction to dilated cardiomyopathy, biventricular dysfunction, and ventricular arrhythmias [5, 6]. Multimodality imaging is central to distinguishing toxic myocardial injury from active inflammatory myocarditis. Echocardiography may reveal ventricular hypertrophy, diastolic dysfunction, right ventricular involvement, and impaired global longitudinal strain, whereas cardiac magnetic resonance (CMR) can identify fibrosis or non‐specific late gadolinium enhancement, sometimes without myocardial edema. In contrast, active autoimmune myocarditis is more often associated with edema‐sensitive abnormalities and imaging evidence of active inflammation, although myocardial involvement may not always parallel systemic disease activity [7, 8]. When diagnostic uncertainty persists and biopsy results would change management, endomyocardial biopsy with ultrastructural analysis may provide diagnostic confirmation [9]. Although most available evidence derives from case reports, small series, and systematic reviews of observational data, the accumulated literature supports a clinically important message: myocardial involvement in SLE should not be automatically attributed to active lupus. Although HCQ remains widely used in SLE because of its established systemic benefits, prolonged antimalarial exposure may lead to clinically significant cardiotoxicity in susceptible individuals. Early recognition of this phenotype and prompt discontinuation of the offending agent may prevent disease progression, guide HF and arrhythmia management, and avoid inappropriate therapeutic escalation [2, 3, 4]. We report a case of suspected probable antimalarial‐associated cardiomyopathy in a patient with clinically inactive SLE, highlighting the importance of integrating systemic disease activity, cumulative antimalarial exposure, multimodality imaging, coronary evaluation, and exclusion of alternative etiologies. Distinguishing inflammatory myocardial injury from chronic toxic cardiomyopathy in SLE is clinically critical because management strategies differ substantially, and inappropriate immunosuppressive escalation may expose patients to avoidable harm. Case History/Examination In June 2025, a 53‐year‐old woman with SLE, diagnosed in 2009, was receiving outpatient treatment with belimumab 400 mg every 30 days and azathioprine 50 mg daily. She had a prolonged history of antimalarial exposure, including HCQ for approximately 3 years at a daily dose of 200 mg, followed by CQ 150 mg daily for approximately 5 years until admission. Based on documented daily doses and treatment duration, the estimated cumulative antimalarial exposure was approximately 492 g, although this should be interpreted as an approximate total exposure rather than a precisely verified lifetime cumulative dose. Her medical history was also notable for hypothyroidism, severe osteoporosis with vitamin D deficiency, migraine, obstructive sleep apnoea, stage 3a chronic kidney disease, and pre‐existing aortic regurgitation associated with externally reported dysplastic/bicuspid aortic valve morphology. Cardiovascular risk modifiers included SLE, chronic kidney disease, obstructive sleep apnoea, postmenopausal status, and aortic valve disease. No toxic exposures or family history of cardiovascular disease were reported. Surgical history included remote tonsillectomy and left total hip arthroplasty. In the month before admission, she had recent infectious complications, including urinary tract infection, Clostridioides difficile associated diarrhea, and suspected parotiditis, all treated before presentation. She presented with a 2‐day history of intermittent substernal chest pressure of moderate‐to‐severe intensity, lasting approximately 10–20 min, radiating to the left upper limb, and associated with paresthesias, palpitations, and dyspnea at rest. Her baseline functional status before this episode was New York Heart Association Class I. She also reported a 1‐week history of rhinorrhoea, odynophagia, and dry cough. Differential Diagnosis, Investigations and Treatment Initial laboratory testing showed elevated high‐sensitivity troponin I of 25,882 ng/L and NT‐proBNP of 29,727 pg/mL, with preserved renal function. Serum potassium, magnesium, and corrected calcium levels were within normal limits. The marked troponin elevation initially raised concern for acute coronary syndrome or active myocarditis; however, subsequent coronary evaluation, low lupus activity, and absence of myocardial edema on CMR argued against these as the dominant mechanisms. Because of persistent symptoms, she underwent home medical evaluation. The initial electrocardiogram showed sinus rhythm at 60 beats/min, left axis deviation, and ventricular bigeminy. Diffuse repolarization abnormalities were observed, characterized by QT‐interval prolongation and prominent U waves (Figure 1A). She was subsequently transferred by ambulance to the emergency department of a quaternary care hospital. An external 24‐h Holter monitor performed in January 2025 had been reported as normal. Electrocardiographic findings. (A) Initial electrocardiogram showing sinus rhythm at 60 bpm, left axis deviation, ventricular bigeminy, QT‐interval prolongation, and prominent U waves. (B) Sinus rhythm with left anterior fascicular block and right bundle branch block pattern, associated with ST‐segment depression and T‐wave inversion. (C) Follow‐up electrocardiogram after antimalarial withdrawal showing improvement in ventricular ectopy and repolarization abnormalities. On the second day of hospitalization, transthoracic echocardiography demonstrated a dilated left ventricle with globally reduced contractility and no regional wall motion abnormalities. The left ventricular ejection (LVEF) fraction was 44%. Severe mitral regurgitation was identified, without mitral stenosis, with a proximal isovelocity surface area radius of 1.0 cm, an effective regurgitant orifice area of 0.40 cm2, and a regurgitant volume of 58 mL. Moderate aortic regurgitation was also documented. These findings contrasted with an external transthoracic echocardiogram from January 2024, which showed preserved left ventricular systolic function, with an ejection fraction of 59%, Grade I diastolic dysfunction, mild mitral regurgitation associated with mitral fibro‐sclerosis, and aortic valve sclerosis with at least moderate‐to‐severe aortic regurgitation. Continuous electrocardiographic monitoring during hospital days 2 and 3 showed sinus rhythm with left axis deviation consistent with left anterior fascicular block, associated with a right bundle branch block pattern. Additional repolarization abnormalities included ST‐segment depression and T‐wave inversion (Figure 1B,C). Given the patient's history of SLE and the possibility of lupus‐related myocardial involvement, rheumatology consultation was requested. Although an initial SLEDAI‐2 K estimate of 6 had been considered while anti‐dsDNA testing was pending, the final rheumatologic assessment supported low disease activity, with a SLEDAI‐2 K score of 2. There was no clinical or serological evidence of active lupus flare. Complement levels, including C3 and C4, were within normal ranges, anti‐dsDNA antibodies were normal, C‐reactive protein and erythrocyte sedimentation rate were normal, and urinalysis showed no proteinuria or active urinary sediment. Given the patient's history of SLE and initial suspicion of lupus‐related myocardial involvement, intravenous methylprednisolone (1000 mg/day) was initiated on hospital day 2. However, after rheumatologic assessment confirmed low SLE disease activity without lupus flare, methylprednisolone was discontinued on the same day. On the fourth day of hospitalization, CMR imaging was performed. The study showed mild left ventricular dilatation, moderate left ventricular systolic dysfunction, and global hypokinesia, with more pronounced wall thinning and hypokinesia in the lateral and apical segments. No myocardial edema was observed on STIR sequences. Late gadolinium enhancement was identified in a mixed pattern, including predominantly subendocardial enhancement in the apical and lateral segments and non‐ischemic mid‐wall enhancement in the anteroseptal segment. Moderate right ventricular systolic dysfunction was also present, along with mitral, aortic, and tricuspid regurgitation (Figure 2). Cardiac magnetic resonance findings. (A) Four‐chamber cine steady‐state free precession sequence showing mild left ventricular dilatation. (B) Short‐axis phase‐sensitive inversion recovery sequence showing subendocardial late gadolinium enhancement in the apical‐lateral segment. (C) Short‐axis phase‐sensitive inversion recovery sequence demonstrating non‐ischemic mid‐wall late gadolinium enhancement in the anteroseptal segment. The CMR findings suggested chronic myocardial injury with mixed ischemic and non‐ischemic features. The anteroseptal mid‐wall enhancement was compatible with non‐ischemic myocardial fibrosis and could reflect prior inflammatory injury, whereas the limited subendocardial apicolateral enhancement raised the possibility of ischemic scar. However, the absence of myocardial edema on STIR sequences made active lupus myocarditis less likely and favored chronic structural myocardial injury. Although normal invasive coronary angiography and a prior calcium score of 0 argued strongly against obstructive epicardial coronary artery disease, they did not fully exclude prior MINOCA, transient coronary thrombosis, vasospasm, or microvascular ischemic injury. Therefore, the limited subendocardial LGE was interpreted cautiously as a possible contributing or competing mechanism rather than as the primary explanation for the entire phenotype. The absence of obstructive epicardial coronary disease was concordant with prior coronary computed tomography angiography from April 2024, which showed a calcium score of 0, and with a myocardial perfusion study from January 2023 showing < 10% ischemia. Although concomitant valvular regurgitation may have contributed to symptoms and ventricular remodeling, the abrupt development of conduction and repolarization abnormalities, ventricular ectopy, mixed late gadolinium enhancement without edema, and subsequent improvement after antimalarial withdrawal favored a superimposed toxic cardiomyopathic process. After integrating the clinical presentation, low lupus activity, new ventricular dysfunction, conduction abnormalities, repolarization changes, ventricular ectopy, absence of myocardial edema, and exclusion of obstructive coronary artery disease, the overall findings supported the diagnosis of probable antimalarial‐associated cardiomyopathy. CQ was discontinued, and rheumatology follow‐up was arranged to reassess long‐term SLE therapy. Endomyocardial biopsy was deferred because the diagnosis was considered clinically probable, the patient demonstrated early improvement after antimalarial withdrawal, and histologic confirmation was unlikely to alter immediate management. The main clinical, diagnostic, and therapeutic milestones are summarized in Table 1. Furthermore, Table 2 outlines the differential diagnosis considered in evaluating myocardial injury in this patient with systemic lupus erythematosus and chronic antimalarial exposure. TABLE 1Clinical timeline.Time pointKey clinical milestoneClinical interpretation/action2009–2025SLE treated with long‐term antimalarials; cumulative exposure ≈92 gRelevant exposure to CQ/HCQJan 2023–Jan 2025Prior low‐risk ischemic evaluation, preserved LVEF, normal HolterBaseline without major systolic dysfunction or arrhythmiaJun 2025 admissionChest pain, dyspnea, palpitations, troponin 25,882 ng/L, NT‐proBNP 29,727 pg/mLAcute myocardial injury and HF phenotypeInitial ECGVentricular bigeminy, QT prolongation, prominent U wavesElectrical myocardial involvementHospital Day 2LVEF 44%, global hypokinesia, severe functional MR, moderate ARNew ventricular dysfunction; valvular contribution consideredHospital Day 4CMR showed biventricular dysfunction, mixed LGE, and no myocardial edema; invasive coronary angiography showed normal epicardial coronary arteriesChronic structural myocardial injury favored overactive myocarditis; obstructive CAD considered unlikelyAfter integrationLow SLEDAI‐2 K, no flare, chronic antimalarial exposureProbable antimalarial‐associated cardiomyopathy; CQ stopped6 monthsClinical improvement, lower ventricular ectopy, LVEF > 50%Partial reversibility after drug withdrawal Note: Timeline developed by the authors based on the patient's clinical course, diagnostic work‐up, therapeutic intervention, and early follow‐up. Chronic antimalarial‐associated cardiomyopathy mimicking lupus myocarditis in systemic lupus erythematosus.Abbreviations: AR, aortic regurgitation; CAD, coronary artery disease; CMR, cardiac magnetic resonance; CQ, chloroquine; ECG, electrocardiogram; HCQ, hydroxychloroquine; HF, heart failure; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NT‐proBNP, N‐terminal pro–B‐type natriuretic peptide; SLE, systemic lupus erythematosus; SLEDAI‐2 K, Systemic Lupus Erythematosus Disease Activity Index 2000. Clinical timeline. Note: Timeline developed by the authors based on the patient's clinical course, diagnostic work‐up, therapeutic intervention, and early follow‐up. Chronic antimalarial‐associated cardiomyopathy mimicking lupus myocarditis in systemic lupus erythematosus. Abbreviations: AR, aortic regurgitation; CAD, coronary artery disease; CMR, cardiac magnetic resonance; CQ, chloroquine; ECG, electrocardiogram; HCQ, hydroxychloroquine; HF, heart failure; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NT‐proBNP, N‐terminal pro–B‐type natriuretic peptide; SLE, systemic lupus erythematosus; SLEDAI‐2 K, Systemic Lupus Erythematosus Disease Activity Index 2000. TABLE 2Differential diagnosis of myocardial injury in a patient with systemic lupus erythematosus and chronic antimalarial exposure.DiagnosisSupporting findingsFindings againstOverall likelihoodLupus myocarditisSLE, chest pain, troponin, LV dysfunctionLow SLEDAI‐2 K, no flare, no edema on CMR, improvement after antimalarial withdrawalLowObstructive CADSubendocardial LGENormal invasive coronary angiography, prior calcium score 0, and absence of obstructive epicardial diseaseLowMINOCA/microvascular injuryLimited subendocardial LGENo acute ischemic ECG pattern, prior low‐risk ischemic testingPossible competing/contributing mechanismInfiltrative/storage diseaseConduction disease, LGENo classic phenotype; chronic antimalarial exposure more plausibleLowValvular cardiomyopathyMR/AR, LV dilationDoes not explain conduction/repolarization abnormalities, ectopy, mixed LGE, improvement after drug withdrawalContributing factorAntimalarial cardiotoxicityChronic exposure, conduction/repolarization abnormalities, biventricular dysfunction, LGE without edema, improvement after withdrawalNo biopsy confirmationMost likely Note: Differential diagnoses and imaging interpretation were based on the patient's clinical findings and supported by contemporary recommendations on myocarditis, cardiac magnetic resonance tissue characterization, MINOCA, and antimalarial‐associated cardiotoxicity [3, 4, 10].Abbreviations: AR, aortic regurgitation; CAD, coronary artery disease; CMR, cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular; MINOCA, myocardial infarction with non‐obstructive coronary arteries; MR, mitral regurgitation; SLE, systemic lupus erythematosus; SLEDAI‐2 K, Systemic Lupus Erythematosus Disease Activity Index 2000. Differential diagnosis of myocardial injury in a patient with systemic lupus erythematosus and chronic antimalarial exposure. Note: Differential diagnoses and imaging interpretation were based on the patient's clinical findings and supported by contemporary recommendations on myocarditis, cardiac magnetic resonance tissue characterization, MINOCA, and antimalarial‐associated cardiotoxicity [3, 4, 10]. Abbreviations: AR, aortic regurgitation; CAD, coronary artery disease; CMR, cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular; MINOCA, myocardial infarction with non‐obstructive coronary arteries; MR, mitral regurgitation; SLE, systemic lupus erythematosus; SLEDAI‐2 K, Systemic Lupus Erythematosus Disease Activity Index 2000. Follow Up Following withdrawal of antimalarial therapy, the patient showed favorable clinical evolution, with improvement in dyspnea, resolution of chest pain, and no recurrence of palpitations during hospitalization. Serial electrocardiograms demonstrated improvement in repolarization abnormalities and reduction of ventricular ectopy compared with the initial tracing. She remained hemodynamically stable and was discharged with outpatient follow‐up by cardiology and rheumatology. At 6‐month follow‐up after antimalarial withdrawal, the patient remained clinically stable, with sustained improvement in dyspnea, no recurrence of chest pain or palpitations, reduced ventricular ectopic burden, and recovery of left ventricular systolic function to an LVEF > 50%. Besides, SLE remained clinically stable without evidence of disease reactivation after CQ withdrawal, while belimumab and azathioprine therapy were continued. Renal function also remained stable, with persistent stage 3a chronic kidney disease and no further deterioration. No additional immunosuppressive therapy was required following CQ discontinuation. These findings supported partial reversibility after antimalarial withdrawal and reinforced the diagnosis of probable antimalarial‐associated cardiomyopathy. Discussion Chronic cardiotoxicity associated with CQ and HCQ is an uncommon but clinically important complication of long‐term antimalarial therapy. In patients with SLE, its recognition is particularly challenging because myocardial injury is frequently attributed to lupus myocarditis [4]. This diagnostic anchoring may delay antimalarial withdrawal and lead to inappropriate escalation of immunosuppression. Our case illustrates this diagnostic pitfall in a patient with clinically inactive SLE who developed myocardial injury, ventricular dysfunction, ventricular ectopy, and conduction/repolarization abnormalities during chronic antimalarial exposure [4, 10]. The clinical phenotype was consistent with previously reported CQ/HCQ cardiotoxicity, which may include conduction disease, ventricular hypertrophy or dilation, hypokinesia, HF, and arrhythmias. These manifestations are biologically plausible because CQ and HCQ act as lysosomotropic agents that increase intralysosomal pH, impair autophagic flux, and induce acquired myocardial phospholipidosis. The resulting cytoplasmic vacuolization, myocyte injury, interstitial fibrosis, and conduction system involvement provide a mechanistic explanation for the overlap between ventricular dysfunction, myocardial scar, and electrical instability [3, 11]. When biopsy is performed, the pathological hallmark of CQ/HCQ cardiotoxicity is a lysosomal storage‐like cardiomyopathy characterized by myocyte vacuolization and distinctive ultrastructural inclusions, including curvilinear bodies and lamellar/myeloid bodies, sometimes described as zebra bodies [5, 6]. The arrhythmic phenotype is clinically important in CQ/HCQ cardiotoxicity. Antimalarial toxicity may involve the conduction system and repolarization reserve, leading to bundle branch block, atrioventricular block, QT prolongation, ventricular ectopy, malignant ventricular arrhythmias, and rarely sudden cardiac death. In our patient, ventricular bigeminy, QT prolongation, prominent U waves, and new conduction/repolarization abnormalities supported electrical myocardial involvement and justified close rhythm surveillance after antimalarial withdrawal [3, 11]. Because parametric mapping was not available, the absence of edema was based on conventional edema‐sensitive imaging and should be interpreted within the limitations of the CMR protocol. The combination of biventricular dysfunction and mixed late gadolinium enhancement without myocardial edema favored chronic structural myocardial injury rather than active inflammatory myocarditis. According to the revised Lake Louise criteria, active myocarditis is supported by both T1‐based evidence of myocardial injury and T2‐based evidence of edema. The absence of myocardial edema did not completely exclude prior or resolving inflammatory injury; however, in the context of low SLEDAI‐2 K activity, absent clinical or serological flare, mixed LGE without T2‐based activity, and improvement after antimalarial withdrawal, active lupus myocarditis was considered unlikely [4, 10, 11]. The subendocardial component of late gadolinium enhancement required careful interpretation because it may suggest prior ischemic injury or MINOCA. However, normal invasive coronary angiography, a previous calcium score of 0, and prior low‐risk ischemic evaluation argued against obstructive epicardial coronary artery disease [11]. Conversely, the concomitant mid‐wall anteroseptal enhancement represented a non‐ischemic pattern of fibrosis [12]. Although CMR findings in antimalarial cardiotoxicity are not pathognomonic, the integration of chronic exposure, clinically inactive lupus, biventricular dysfunction, conduction disease, ventricular ectopy, LGE without edema, normal epicardial coronary anatomy, and early improvement after drug withdrawal supported the diagnosis of probable antimalarial‐associated cardiomyopathy [3]. Based on this diagnostic reasoning, we propose a practical diagnostic approach for patients with SLE who develop myocardial injury during chronic antimalarial exposure (Figure 3). Proposed diagnostic approach to myocardial injury in systemic lupus erythematosus during chronic antimalarial exposure. The algorithm emphasizes the integration of lupus disease activity, cumulative chloroquine/hydroxychloroquine exposure, electrocardiographic abnormalities, cardiac magnetic resonance findings, coronary evaluation, and exclusion of alternative or contributing diagnoses. In patients with clinically inactive SLE, conduction abnormalities, ventricular ectopy, ventricular dysfunction, LGE without myocardial edema, and normal epicardial coronary arteries support the diagnosis of probable antimalarial‐associated cardiomyopathy. CAD, coronary artery disease; CMR, cardiac magnetic resonance; CQ, chloroquine; ECG, electrocardiogram; HCQ, hydroxychloroquine; LGE, late gadolinium enhancement; MINOCA, myocardial infarction with non‐obstructive coronary arteries; SLE, systemic lupus erythematosus. Several alternative or contributing diagnoses were considered. Valvular regurgitation may have contributed to symptoms and ventricular remodeling, particularly given the presence of severe functional mitral regurgitation and moderate aortic regurgitation; however, it did not fully explain the new conduction/repolarization abnormalities, ventricular ectopy, biventricular involvement, or myocardial fibrosis pattern [13, 14]. The temporal association between CQ withdrawal and clinical, electrocardiographic, arrhythmic, and echocardiographic improvement strengthened the suspicion of drug‐related cardiotoxicity, although spontaneous recovery from a transient inflammatory or ischemic insult cannot be completely excluded. Infiltrative and storage cardiomyopathies may also present with conduction disease and LGE, but the absence of a classic infiltrative phenotype and the presence of chronic antimalarial exposure favored drug‐induced toxicity. Toxicity related to azathioprine or belimumab was considered less likely, given the absence of a well‐established chronic cardiomyopathic phenotype comparable to CQ/HCQ‐associated lysosomal injury [15, 16]. This diagnostic distinction has direct therapeutic implications. Once antimalarial cardiotoxicity is suspected, discontinuation of the offending drug is the cornerstone of management; however, this decision must be balanced against the risk of SLE reactivation. Therefore, alternative strategies to maintain adequate disease control should be reassessed in conjunction with rheumatology, particularly because lupus myocarditis remains an important concern if disease activity recurs [3, 4, 10]. In our patient, belimumab and azathioprine were continued after CQ withdrawal, with no evidence of SLE reactivation at 6‐month follow‐up. At 6‐month follow‐up after antimalarial withdrawal, she remained clinically stable, with sustained improvement in dyspnea, no recurrence of chest pain or palpitations, reduced ventricular ectopic burden, and recovery of left ventricular systolic function to an LVEF > 50%. This favorable evolution was consistent with at least partial reversibility of drug‐related cardiotoxicity; however, continued rhythm surveillance and serial imaging remain warranted because conduction disease, ventricular arrhythmias, and myocardial fibrosis may persist despite clinical recovery [3, 4, 10]. Although histological confirmation was not available, the temporal association between chronic antimalarial exposure, development of a compatible electrical and myocardial phenotype, exclusion of obstructive coronary disease and active lupus flare, and subsequent clinical, arrhythmic, and echocardiographic improvement after drug withdrawal supports a probable drug‐associated cardiomyopathy. This case has limitations. Endomyocardial biopsy was not performed; therefore, the diagnosis remains probable rather than histologically confirmed by characteristic findings such as lysosomal storage–like cardiomyopathy, myocyte vacuolization, curvilinear bodies, and lamellar/myeloid inclusions. Biopsy was deferred because the diagnosis was clinically probable, the patient showed early improvement after antimalarial withdrawal, and histologic confirmation was unlikely to alter immediate management. Moreover, quantitative CMR mapping parameters, including native T1, T2 mapping, and extracellular volume, were not available, limiting tissue characterization. Although follow‐up demonstrated clinical improvement, reduction in ventricular ectopic burden, and recovery of LVEF to greater than 50%, longer‐term follow‐up is required to determine the durability of ventricular recovery, residual arrhythmic risk, and progression or regression of myocardial fibrosis. Besides, despite an estimated cumulative antimalarial exposure being calculated, the exact lifetime cumulative dose could not be fully reconstructed from the available medical records, limiting precise dose‐toxicity correlation. Finally, although the overall clinicodiagnostic coherence favored probable antimalarial‐associated cardiomyopathy, a multifactorial contribution from valvular disease, prior inflammatory injury, or microvascular ischemia cannot be completely excluded. Conclusion In patients with SLE, myocardial injury should not be automatically attributed to active lupus. Antimalarial cardiotoxicity is an important diagnostic mimic of lupus myocarditis and should be considered when chronic exposure coexists with unexplained myocardial injury, ventricular dysfunction, conduction abnormalities, ventricular arrhythmias, and CMR evidence of chronic myocardial injury without edema. Early recognition may prevent inappropriate immunosuppression escalation and allow timely drug withdrawal, HF optimization, and arrhythmic risk stratification. Author Contributions María Camila Bernal Beltrán: conceptualization, data curation, investigation, formal analysis, writing – original draft, writing – review and editing. Ángel Alberto García Peña: conceptualization, investigation, writing – original draft, methodology, writing – review and editing, formal analysis, data curation, project administration, supervision, validation. Diego Alejandro Ortega: conceptualization, investigation, writing – original draft, writing – review and editing, formal analysis, data curation. Diego Armando Pérez Covo: conceptualization, data curation, formal analysis, investigation, methodology, project administration, supervision, validation, writing – original draft, writing – review and editing. Cristian Orlando Porras Bueno: conceptualization, writing – original draft, investigation, writing – review and editing, formal analysis, data curation. Emilio José Juan Guardela: conceptualization, investigation, writing – original draft, writing – review and editing, formal analysis, data curation. Alejandro Mariño Correa: conceptualization, writing – original draft, investigation, writing – review and editing, formal analysis, data curation. Laura Valentina Omaña Álvarez: conceptualization, investigation, writing – original draft, writing – review and editing, formal analysis, data curation. Carlos Hernán Calderón: conceptualization, writing – original draft, writing – review and editing, formal analysis, data curation, investigation. Edward Andres Cáceres Méndez: conceptualization, investigation, writing – original draft, writing – review and editing, formal analysis, data curation. Funding This article was funded by Pontificia Universidad Javeriana. Ethics Statement The publication of this case has been approved by the institutional ethics committee. Consent In accordance with the journal's policy on patient consent, written informed consent was obtained from the patient for publication of this report. Conflicts of Interest The authors declare no conflicts of interest.